Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Price Target Raised to $60.00

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) had its price target raised by Guggenheim from $40.00 to $60.00 in a report published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other research analysts have also issued research reports about the stock. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Wedbush raised their price objective on Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Thursday, July 30th. Jefferies Financial Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They set a “buy” rating and a $50.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $45.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $46.50.

Damora Therapeutics, Inc. Common Stock Stock Performance

NASDAQ:DMRA opened at $20.66 on Friday. The company has a 50-day moving average of $28.43 and a 200-day moving average of $26.33. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -6.13 and a beta of 1.46. Damora Therapeutics, Inc. Common Stock has a twelve month low of $3.50 and a twelve month high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its earnings results on Monday, August 10th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.06. On average, research analysts forecast that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current year.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of hedge funds have recently modified their holdings of DMRA. Arizona State Retirement System acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the second quarter worth $260,000. Squarepoint Ops LLC acquired a new position in Damora Therapeutics, Inc. Common Stock during the second quarter valued at $303,000. Seven Fleet Capital Management LP acquired a new position in Damora Therapeutics, Inc. Common Stock during the second quarter valued at $7,398,000. Finally, Braidwell LP purchased a new stake in Damora Therapeutics, Inc. Common Stock in the 2nd quarter worth about $42,146,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.